UTI vaccine safety and immune response study for adults 18-64
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new vaccine to prevent urinary tract infections (UTIs). It first checks safety and immune response in healthy adults, then in women with recent E. coli UTIs. The goal is to see if the vaccine can reduce future infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 64 years old.
- For part 2, be a female with at least one E. coli UTI confirmed by a urine culture in the last year.
- Have no serious health problems like a weakened immune system or severe allergies.
- Not be pregnant, breastfeeding, or planning pregnancy during the study (females).
- Avoid other investigational drugs or vaccines during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests LBP-EC01 to treat a bladder infection (UTI) caused by drug-resistant E. coli. It may help by targeting the specific bacteria that make UTIs harder to cure with common antibiotics.
This study looks at complicated urinary tract infections (UTIs), which are infections in the urinary system that happen when there is an underlying issue like a urinary catheter, blockage, or other urinary tract problem. The trial aims to gather information to better understand and treat these infections.
This study looks at urine infections caused by certain resistant bacteria. If you had a UTI treated by your family doctor between June and December 2024, your doctor may help us learn more about these infections and how to treat them better.
This trial studies different ways to prevent repeated bladder (urinary tract) infections in women. It may help people who keep getting these infections by testing safer or more effective prevention strategies.
This study tests an experimental vaccine designed to protect against E. coli bacteria. It is for healthy adults aged 18 to 63 who want to help researchers see if the vaccine is safe and produces an immune response.
This study tests a new medicine called TUL108 in a small group of healthy people to see if it is safe and how the body handles it. You would receive either one dose or multiple doses of the medicine or a placebo, and your health will be closely monitored.
Hear when a new Urinary Tract Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.